Literature DB >> 6117506

Radioimmunoassay study of hepatic clearance and disappearance half-time of somatostatin and vasoactive intestinal peptide in dogs.

J A Chayvialle, P L Rayford, J C Thompson.   

Abstract

The effects of hepatic transit on concentrations of synthetic cyclic (ovine) somatostatin and of highly purified (porcine) vasoactive intestinal peptide were studied in five conscious dogs prepared with indwelling portal catheters. The peptides were infused via peripheral vein catheters or the portal catheters for 40 minutes at actual integrated doses of 2.8 pmol/kg/min for vasoactive intestinal peptide an 8.2 pmol/kg/min for somatostatin. Specific radioimmunoassays were used for the measurement of the circulating peptides. As estimated from the plateau peptide concentrations achieved a hindleg vein during the portal and the peripheral infusions, the transhepatic loss of immunoreactive vasoactive intestinal peptide was 72.9 +/- 2.1%, against 27.5 +/- 12.5% for somatostatin. For the given doses of peptides infused systematically, the half-life, metabolic clearance rate, and distribution volume were, respectively, 1.80 +/- 0.1 minutes, 39.3 +/- 5.2 ml/kg/min, and 103.7 +/- 14.8 ml/kg for vasoactive intestinal peptide, and 1.0 +/- 0.2 minutes, 95.2 +/- 12.5 ml/kg/min, and 114.7 +/- 6.0 ml/kg for somatostatin. These results indicate that (ovine) somatostatin and (porcine) vasoactive intestinal peptide are both readily cleared from plasma in dogs. In the present experimental conditions, vasoactive intestinal peptide, but not somatostatin, was rapidly altered through hepatic transit so that it escaped recognition by the assay system.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6117506      PMCID: PMC1419860          DOI: 10.1136/gut.22.9.732

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  19 in total

1.  Suppression of gastrin release and gastric secretion by gastric inhibitory polypeptide (GIP) and vasoactive intestinal polypeptide (VIP).

Authors:  H V Villar; H R Fender; P L Rayford; S R Bloom; N I Ramus; J C Thompson
Journal:  Ann Surg       Date:  1976-07       Impact factor: 12.969

Review 2.  Somatostatin. Physiology and clinical applications.

Authors:  J E Gerich; G S Patton
Journal:  Med Clin North Am       Date:  1978-03       Impact factor: 5.456

3.  Distribution, ontogeny and ultrastructure of somatostatin immunoreactive cells in the pancreas and gut.

Authors:  J Alumets; F Sundler; R Håkanson
Journal:  Cell Tissue Res       Date:  1977-12-28       Impact factor: 5.249

4.  Effects of synthetic vasoactive intestinal peptide (VIP), secretin and their partial sequences on gastric secretion.

Authors:  G M Makhlouf; A M Zfass; S I Said; M Schebalin
Journal:  Proc Soc Exp Biol Med       Date:  1978-04

5.  Possible dual role for vasoactive intestinal peptide as gastrointestinal hormone and neurotransmitter substance.

Authors:  M G Bryant; M M Polak; I Modlin; S R Bloom; R H Albuquerque; A G Pearse
Journal:  Lancet       Date:  1976-05-08       Impact factor: 79.321

6.  Synthesis and pharmacological properties of the N-terminal decapeptide of the vasoactive intestinal peptide (VIP).

Authors:  M Bodanszky; J B Henes; A E Yiotakis; S I Said
Journal:  J Med Chem       Date:  1977-11       Impact factor: 7.446

7.  Pancreatic and gastric somatostatin release in response to intragastric and intraduodenal nutrients and HCl in the dog.

Authors:  V Schusdziarra; V Harris; J M Conlon; A Arimura; R Unger
Journal:  J Clin Invest       Date:  1978-09       Impact factor: 14.808

8.  Inhibition by somatostatin (growth-hormone release-inhibiting hormone, GH-RIH) of gastric acid and pepsin and G-cell release of gastrin.

Authors:  A A Barros D'sa; S R Bloom; J H Baron
Journal:  Gut       Date:  1978-04       Impact factor: 23.059

9.  Structure-activity relationships of eighteen somatostatin analogues on gastric secretion.

Authors:  M P Brown; D H Coy; A Gomez-Pan; B H Hirst; M Hunter; C Meyers; J D Reed; A V Schally; B Shaw
Journal:  J Physiol       Date:  1978-04       Impact factor: 5.182

10.  Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects.

Authors:  S Domschke; W Domschke; S R Bloom; P Mitznegg; S J Mitchell; G Lux; U Strunz
Journal:  Gut       Date:  1978-11       Impact factor: 23.059

View more
  5 in total

Review 1.  Endogenous somatostatin and the gut.

Authors:  M R Lucey
Journal:  Gut       Date:  1986-04       Impact factor: 23.059

Review 2.  Biochemistry and physiology of gastrointestinal somatostatin.

Authors:  M R Lucey; T Yamada
Journal:  Dig Dis Sci       Date:  1989-03       Impact factor: 3.199

3.  Substance P, vasoactive intestinal polypeptide, and gastrin catabolism in canine liver and kidney.

Authors:  T Kabemura; T Misawa; Y Chijiiwa; T Nasu; H Nawata
Journal:  Dig Dis Sci       Date:  1992-11       Impact factor: 3.199

4.  Contribution of the pancreas to circulating somatostatin-like immunoreactivity in the normal dog.

Authors:  G J Taborsky; J W Ensinck
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

5.  Sodium depletion decreases hepatic metabolism of vasoactive intestinal peptide in the rabbit.

Authors:  K A Duggan; C M Hawley; G J Macdonald; S Shelley
Journal:  J Physiol       Date:  1989-11       Impact factor: 5.182

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.